WO2010009582A1 - 药疗鞋 - Google Patents

药疗鞋 Download PDF

Info

Publication number
WO2010009582A1
WO2010009582A1 PCT/CN2008/001542 CN2008001542W WO2010009582A1 WO 2010009582 A1 WO2010009582 A1 WO 2010009582A1 CN 2008001542 W CN2008001542 W CN 2008001542W WO 2010009582 A1 WO2010009582 A1 WO 2010009582A1
Authority
WO
WIPO (PCT)
Prior art keywords
container
powder
cases
volatile oil
mixed
Prior art date
Application number
PCT/CN2008/001542
Other languages
English (en)
French (fr)
Inventor
乌力吉
Original Assignee
Wu Liji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wu Liji filed Critical Wu Liji
Priority to EP08800540.0A priority Critical patent/EP2311340B1/en
Publication of WO2010009582A1 publication Critical patent/WO2010009582A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A43FOOTWEAR
    • A43BCHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
    • A43B1/00Footwear characterised by the material
    • A43B1/0045Footwear characterised by the material made at least partially of deodorant means
    • AHUMAN NECESSITIES
    • A43FOOTWEAR
    • A43BCHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
    • A43B17/00Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined
    • A43B17/10Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined specially adapted for sweaty feet; waterproof
    • AHUMAN NECESSITIES
    • A43FOOTWEAR
    • A43BCHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
    • A43B7/00Footwear with health or hygienic arrangements
    • A43B7/14Footwear with health or hygienic arrangements with foot-supporting parts
    • A43B7/1405Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form
    • A43B7/1455Footwear with health or hygienic arrangements with foot-supporting parts with pads or holes on one or more locations, or having an anatomical or curved form with special properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body
    • A61M35/10Wearable devices, e.g. garments, glasses or masks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Definitions

  • the invention relates to a medicine shoe, in particular to leather shoes, cotton shoes, sandals, slippers and various types of shoes. Background technique
  • the object of the present invention is to provide a medical treatment shoe which can promote the blood circulation of the human foot under the premise of not affecting people's normal work, and can treat various chronic diseases. And the role of prevention.
  • a medicine shoe characterized in that: the insole of the sole is provided with at least one concave groove, and any number of containers of any size are respectively placed in the four traps, and the bottom of the container is provided with a container bottom, and the container is provided with a hole or a container. Covered with a cloth for volatilizing from the hole or cloth, the container containing a pharmaceutical composition having a therapeutic effect, the pharmaceutical composition comprising at least a powder selected from a powder, a liquid, and a volatile oil.
  • the insole of the sole is provided with at least one concave groove, and any number of containers of any size are respectively placed in the four traps, and the bottom of the container is provided with a container bottom, and the container is provided with a hole or a container. Covered with a cloth for volatilizing from the hole or cloth, the container containing a pharmaceutical composition having a therapeutic effect, the pharmaceutical composition comprising at least a powder selected from a powder, a liquid, and a volatile oil.
  • the container is an upper cover with an inner card edge or an inner arc-shaped card edge and a hole, and the outer edge has an outer card edge or an outer arc shape.
  • the bottom box of the card edge is fastened up and down.
  • the container includes a buckle with an inner card edge or an inner circular arc-shaped card edge, and a bottom box with an outer card edge or an outer arc-shaped card edge.
  • the upper and lower buckles are formed, and the buckles engage at least one layer of fabric at the opening of the bottom box.
  • At least one container bottom is disposed at the bottom of the container to prevent the container from being dislocated or misaligned after being collapsed by the foot, and the container bottom is disposed under the corresponding position of the bottom of the container.
  • the upper end of the container holder preferably reaches the lower surface of the insole, and the thickness of the container holder may vary according to the thickness of the sole.
  • the container and the container holder may be made of any material, such as a circular shape, a square shape, and a special shape. Or any shape of any size and any size.
  • the powdered powder and the liquid medicament are all prepared from a single tablet of borneol, and the weight ratio of the above-mentioned water tablet is 1 to 9 parts by weight.
  • the powder medicine powder and the liquid medicine agent are all prepared by combining one kind of medicine borneol, and further adding a medicine including clove, white cardamom, angelica, medlar, white peony, eucalyptus, etc., or by
  • a medicine including clove, white cardamom, angelica, medlar, white peony, eucalyptus, etc.
  • the above-mentioned any kind of medicine is prepared by separately combining with the water piece, and the weight ratio of the above-mentioned raw materials such as borneol, clove, white soybean meal, Chinese angelica, medlar, white peony and eucalyptus is 1 - 9 parts by weight, respectively.
  • the preparation method of the powder medicine powder and the liquid medicine comprises the following steps:
  • Each of the raw material powders is separately added to the borneol to obtain the single-flavor powder powder. If the powder powder is mixed, the single powder powders are mixed with each other.
  • the powdered powders of the above-mentioned powders are separately immersed in an aqueous solution containing acetic acid or glacial acetic acid, and then separately extracted by exudation to obtain the extracts of the remaining raw materials, and then the granules which are ground into powder are added.
  • the separate extraction stock solution the individual liquid medicaments are obtained, and if the liquid medicaments to be mixed are mixed, the single liquid medicaments are mixed with each other.
  • the composition of the volatile oil composition comprises: clove oil, eugenol, clove basil oil, eucalyptus oil and borneol, and the weight ratio thereof is 1 - 9 parts by weight, respectively.
  • the method for preparing the volatile oil composition comprises the following steps:
  • Each of the above-mentioned volatile oil raw materials is separately added to the borneol to obtain the single-flavored volatile oil composition, and if the volatile oil composition to be mixed is mixed, the single-flavored volatile oil composition is mixed with each other.
  • the two liquid dosage forms of the liquid medicine and the volatile oil composition may be mixed and dropped into the empty container; or the liquid medicine and the volatile oil composition may be used in two dosage forms. After mixing, it is used by dropping into the container containing the powder of the agent; and the two dosage forms of the liquid agent and the volatile oil composition may be separately dropped into the container containing the powdered powder. .
  • the present invention has the following beneficial effects:
  • the powder powder, the liquid medicament and the volatile oil composition are all placed in a container, and the container has a hole The upper cover of the hole or the cloth is provided so that the powder powder, the liquid medicament and the volatile oil composition can be volatilized.
  • the powder powder, the liquid medicament and the volatile oil composition of the present invention can each be used alone to exert a therapeutic effect, and can also be used in combination to exert a larger and better therapeutic effect.
  • Figure 1 is a perspective view of a medical shoe
  • Figure 2 is a perspective view of the insole
  • Figure 3 is a cross-sectional view of the insole
  • Figure 4 is a perspective view of the insole container
  • Figure 5 is a cross-sectional view of the insole container
  • Figure 6 is a perspective view of the sole container bottom support
  • Figure 7 is a cross-sectional view of the sole container holder
  • FIGS. 8 and 9 are respectively a combined perspective view and an exploded perspective view of an embodiment of a container
  • Fig. 10 and Fig. 11 are respectively a combined perspective view and an exploded perspective view of another embodiment of the container
  • Fig. 12 and Fig. 13 are respectively a container A combined perspective view and an exploded perspective view of still another embodiment
  • FIGS. 14 and 15 are respectively a combined perspective view and an exploded perspective view of still another embodiment of the container.
  • the invention relates to a mechanism and a structural design of a medical treatment function, which are arranged in single shoes, cotton shoes, sandals, shoes and various types of shoes.
  • the medical shoe includes an insole 1 1 , the insole 11 is provided with at least one recessed groove 12 , and the container 13 is disposed in the recessed groove 12 , and the sole of the bottom of the container 13 is provided.
  • a container holder 15 is provided at a position corresponding to the recessed groove 12.
  • FIG. 2 and Fig. 3 it is a perspective view and a cross-sectional view of the insole 1 1 , and the insole 1 1 is provided with a recessed groove 12.
  • FIG. 4 and FIG. 5 it is a perspective view and a cross-sectional view of the insole 1 1 in which the container 13 is placed, the insole A container 13 is provided in the recessed groove 12 of 11.
  • FIG. 6 and FIG. 7 it is a perspective view and a cross-sectional view of a sole 14 of a medical shoe.
  • the sole 14 is provided with a container holder 15 , and the container holder 15 is disposed at a corresponding position of the insole 11 for placing the container 13 .
  • the lower part is to prevent the container 13 from being displaced or misplaced after being collapsed by the foot.
  • the upper end of the container holder 15 preferably reaches the lower surface of the insole 11.
  • the thickness of the container holder 15 may vary according to the thickness of the sole 14.
  • the container 13 and the container holder 15 may be made of any material, such as a circle or a square. Any shape or any shape of any shape.
  • the container 13 is formed by fastening an upper cover 131 having an inner rim and a hole, and a bottom case 132 having an outer rim on the outer edge.
  • the container 13 includes a buckle 133 with an inner rim and a bottom box 132 with an outer rim, and the buckle 133 has at least one layer of fabric 137. Engaged in the opening of the bottom box 132.
  • the container 13 is formed by an upper cover 134 having an inner circular arc-shaped hem and a hole, and a bottom case 135 having an outer circular arc-shaped hem. .
  • the container 13 includes a buckle 133 having an inner arc-shaped card edge and a bottom box 132 having an outer arc-shaped card edge, and the buckle ring 133 will be at least one.
  • the layer fabric 137 is engaged at the opening of the bottom case 132.
  • the container 13 is provided with a hole or container 13 covered with a cloth 137 for volatilizing the drug from the hole or cloth 137, and the container 13 contains a pharmaceutical composition having a therapeutic effect, the pharmaceutical composition comprising at least: One of a powder powder, a liquid medicament and a volatile oil composition.
  • the powder powder and the liquid medicament component may include only a water piece.
  • the preparation method of the powder powder is as follows: the borneol is finely screened, ground into powder and sieved to obtain the powder powder.
  • the preparation method of the liquid medicament is as follows: the borneol is ground into a powder, and then placed in an aqueous solution containing glacial acetic acid or glacial acetic acid to obtain the liquid medicament.
  • the powder powder and the liquid medicine component may further comprise other auxiliary components, for example, including Ding and water tablets, and each of the raw materials accounts for 1 to 9 parts by weight.
  • Weighing raw materials Weigh each raw material according to the weight ratio of ingredients, for example: weigh 1 part by weight of cloves and 9 parts by weight of water tablets or 9 parts by weight of cloves and 1 part by weight of water tablets.
  • the powders of all the raw materials are mixed and the powder powder is obtained.
  • the preparation method of the liquid medicament described below includes the following steps:
  • Weighing raw materials Weigh each raw material according to the weight ratio of ingredients; for example: weigh 1 part by weight of cloves and 9 parts by weight of borneol or 9 parts by weight of cloves and 1 part by weight of water tablets.
  • the finely-formed water piece is added to the mixed extract liquid to obtain the liquid medicament.
  • other raw material components may be added, and the added raw material components include: clove, white cardamom, angelica, medlar, white peony, cockroach Wood, each raw material is 1 - 9 parts by weight.
  • each raw material Weigh each raw material according to the weight ratio of ingredients, for example: weigh 9 parts by weight of borneol, 1 part by weight of clove, 1 part by weight of white soybean meal, 1 part by weight of angelica, 1 part by weight of medlar, 1 part by weight of peony, ⁇ 1 part by weight of wood, 1 part by weight of borneol, 9 parts by weight of clove, 9 parts by weight of white soybean meal, 9 parts by weight of angelica, 9 parts by weight of zedoary turmeric, 9 parts by weight of peony, and 9 parts by weight of eucalyptus.
  • ingredients for example: weigh 9 parts by weight of borneol, 1 part by weight of clove, 1 part by weight of white soybean meal, 1 part by weight of angelica, 1 part by weight of medlar, 1 part by weight of peony, ⁇ 1 part by weight of wood, 1 part by weight of borneol, 9 parts by weight of clove, 9 parts by weight of white soybean meal, 9 parts by weight of angelica,
  • Each of the raw material powders is separately added to the borneol to obtain the single-flavor powder powder. If the powder powder is mixed, the single powder powders are mixed with each other.
  • the preparation method of the liquid medicament described below includes the following steps:
  • each raw material Weigh each raw material according to the weight ratio of ingredients, for example: weigh 9 parts by weight of borneol, 1 part by weight of clove, 1 part by weight of white soybean meal, 1 part by weight of angelica, 1 part by weight of medlar, 1 part by weight of peony, ⁇ 1 part by weight of wood, or 1 part by weight of water sheet, 9 parts by weight of clove, 9 parts by weight of white soybean meal, 9 parts by weight of angelica, 9 parts by weight of zedoary turmeric, 9 parts by weight of peony, and 9 parts by weight of eucalyptus.
  • ingredients for example: weigh 9 parts by weight of borneol, 1 part by weight of clove, 1 part by weight of white soybean meal, 1 part by weight of angelica, 1 part by weight of medlar, 1 part by weight of peony, ⁇ 1 part by weight of wood, or 1 part by weight of water sheet, 9 parts by weight of clove, 9 parts by weight of white soybean meal, 9 parts by weight of angelica, 9 parts
  • Each of the raw material powders is separately added to the borneol to obtain the single-flavor powder powder. If the powder powder is mixed, the single powder powders are mixed with each other.
  • the above powder powders are respectively immersed in an aqueous solution containing glacial acetic acid or acetic acid, and then separately extracted and obtained to extract the other raw materials, and then the finely ground water is added to the powder.
  • the separate extraction stock solution the individual liquid medicaments are obtained, and if the liquid medicaments to be mixed are mixed, the single liquid medicaments are mixed with each other.
  • the ingredients thereof include: borneol, clove oil, eugenol, Clove basil oil, eucalyptus oil, each raw material accounts for 1 ⁇ 9 parts by weight.
  • each raw material Weigh each raw material according to the weight ratio of ingredients; for example: weigh 9 parts by weight of water tablets, 1 part by weight of clove oil, 1 part by weight of clove basil oil, 1 part by weight of eugenol, 1 part by weight of eucalyptus oil or water 1 part by weight of the tablet, 9 parts by weight of clove oil, 9 parts by weight of clove basil oil, 9 parts by weight of eugenol, and 9 parts by weight of eucalyptus oil.
  • each of the above-mentioned volatile oil raw materials is separately added to the water piece to obtain the single-flavored volatile oil composition, and if the volatile oil composition to be mixed is mixed, the single-flavored volatile oil composition is mixed with each other. .
  • the liquid drug and the volatile oil composition may be mixed into two types and then dropped into an empty container; or the liquid drug or volatile oil composition may be used in two dosage forms.
  • Each of the liquid medicine and the volatile oil composition may be mixed into the container containing the powdered powder, and the mixture may be dropped into the container containing the powdered powder.
  • the insole 11 of the medical shoe is provided with a container 13 containing a powder powder, a liquid medicine, and a volatile oil composition, and a medicine in the container 13, which provides a medicine for the wearer's foot, and the medicine thereof.
  • Pharmacological action can be absorbed through the skin, promote blood circulation, active cells, promote blood circulation and microcirculation, and play a role in the body's treatment and health care.
  • femoral head Necrosis, low back, weakness, insomnia, constipation, benign prostatic hyperplasia, bronchitis, allergic asthma, allergic rhinitis, neurodermatitis, eczema, drug eruption, anemia, gastritis, enteritis, kidney disease, gynecological diseases, etc. It can treat several diseases with the same disease, high recovery rate, safe and practical, simple and easy.
  • the recessed groove 12 on the insole 1 and the container 13 and the container holder 15 on the sole 14 can be made of any material, such as a circular shape, a square shape, a special shape or an arbitrary shape of any shape. Due to the simple structural change, it is easy to understand. Therefore, it is not shown.
  • the bone density is increased, and the hematopoietic function of the bone marrow stem cells is enhanced:
  • Bone cheese is a human body scaffold.
  • Bone marrow stem cells are hematopoietic plants that produce red blood cells, white blood cells, and platelets. After wearing the shoes, the wearer's foot can be provided with medical treatment measures, and the pharmacological action of the drug can be absorbed through the foot, promoting blood circulation, active cells, promoting blood circulation and microcirculation of the human body. It is fluent and vigorous, and it plays a role in the body's treatment. At this time, the red blood cells will be more active under the action of the medicine, and the red blood cells can be fully supplemented by the biological current, carrying oxygen and curl deformation, and the speed of the forward spiral movement is accelerated. Red blood cells will quickly clear the capillary beds in the bones and bone marrow membranes, and the blood circulation in the bones and bone marrow membranes will be smooth.
  • the bones When the blood circulation of the bones is fluent, the bones can obtain a large supply of collagen fiber bundles and vitamins VIII, D, and C from the blood, so that the formation of the bone matrix is ensured.
  • the bones and 4 bow salts in the blood can be deposited on the bone matrix, so that the bone density is increased, the waist and legs are firm, go upstairs or take a long road, not tired, weak, no backache, and make The problem of frequent leg cramps is also eliminated in middle-aged and elderly people due to calcium deficiency and hypoxia.
  • red blood cells clear the capillary bed in the bone and the bone marrow membrane, they can transfer the biological current carried by themselves to the bone marrow stem cells, ie, the red bone marrow.
  • the bone marrow stem cells are adequately supplemented by bioelectric currents, as well as adequate supply of blood and oxygen. Therefore, the hematopoietic function of bone marrow stem cells can be enhanced, and mature red blood cells, white blood cells, and platelets can be produced in time. Moreover, the number of generated blood cells can be kept within normal values.
  • the hematopoietic function of the bones and bone marrow stem cells of the middle-aged and elderly people can be maintained in an active state for a long period of time. Therefore, it is possible to eliminate various types of inflammation and swelling of the middle-aged and elderly people after wearing the shoes, without backache, leg pain, strong waist and legs, energetic, physical enhancement, improved immunity, and basically no cold. Moreover, after wearing the shoes, it can also prolong life and delay aging.
  • Patient Source All cases were diagnosed hypertensive patients in the outpatient department. During the observation period, except for the phase I hypertension, the antihypertensive drugs were stopped. The patients with stage II hypertension continued to use the drugs. The blood pressure was measured regularly, twice a day. During the observation, the blood pressure decreased and the antihypertensive drugs were stopped or stopped. Take antihypertensive drugs. Three of the 30 patients had m-stage hypertension.
  • Clinical effect grade standard (The therapeutic effect of the treatment device is divided into four levels according to cure, marked effect, effective and ineffective, and other instruments refer to implementation)
  • 1 diastolic blood pressure drop is less than 1.33kPa, but has reached the normal range.
  • Diastolic blood pressure decreased by 1.33-2.53kPa before treatment, but did not reach the normal range.
  • 3 systolic blood pressure decreased by 4.00 kPa or more before treatment.
  • Typical cases Patient Han Zhongchang, male, age 58 years old, weight 76kg, Inner Mongolia foreign trade cadre, diagnosed with hypertension for 6 years, has been taking antihypertensive drugs intermittently. Symptoms: Dizziness, chest tightness, blood pressure up to 180/120mmHg. The patient started wearing the shoes on December 5, 1995. On the second day, the blood pressure dropped to normal (because the family was working as a doctor, and the blood pressure was measured three or four times a day). After stopping the shoes for 3 days, the blood pressure rose slightly, and Wear shoes and stop taking antihypertensive drugs. Self-report, dizziness, chest tightness symptoms improved significantly. ECG examination S_T segment down is better than before. Blood, urine Rt is normal.
  • Clinical trial conclusion The clinical observation of 30 cases of hypertensive patients has certain curative effect on improving the symptoms and blood pressure of hypertension. In some patients with mild hypertension, the antihypertensive drugs can not be reduced to normal, and some moderately Hypertension is stopped by antihypertensive drugs due to lower blood pressure, and the dizziness and headache common to hypertension are more obvious.
  • Patient Source Thirty patients were diagnosed with diabetes diagnosed in accordance with the Diabetes Diagnostic Criteria developed by the World Health Organization's Diabetes Expert Committee in 1980. Outpatients from Hohhot area, and can cooperate with doctors to accept visitors. Among the 30 cases, 25 were light and 5 were medium. Among the 25 cases of light type, 5 cases were controlled by diet and 20 cases were taken by oral hypoglycemic drugs. Five patients were treated with insulin, but 30 patients were able to participate in normal work and labor without serious acute or chronic complications.
  • Clinical effect grade standard (The therapeutic effect of the treatment device is divided into four levels according to cure, marked effect, effective and ineffective, and other instruments refer to implementation)
  • the shoes not only have a therapeutic effect, but also are good health care products for diabetics. They are comfortable, soft and painless to wear, and have a protective effect on diabetics.
  • the shoe has no adverse reactions during use.
  • Number of cases The total number is 30 cases, including 20 males and 10 females, aged 36-65 years. The milder cases were 10 cases, moderate in 19 cases, and severe in 1 case.
  • Patient Source All outpatients who were previously diagnosed with coronary heart disease.
  • Clinical effect level standard (The therapeutic effect of the treatment device is divided into four levels according to cure, marked effect, effective and ineffective, and other instruments are referred to)
  • Typical case Patient An Zhiguo, male, 51 years old, weight 70.5kg, chest tightness, dizziness, pain in the precordial area for more than 3 years, through the heart "B" supercardiogram to diagnose coronary heart disease, has been taking crown-expanding anticoagulant therapy, 12 The shoes were worn on the 5th of the month, and the anticoagulant drugs were taken at the same time. After 3 days, the chest tightness was relieved. After 1 week, the chest tightness, palpitations, and pain in the precordial area were alleviated. After 20 days, the electrocardiogram was almost normal. After 40 days, the electrocardiogram was basically normal, and other symptoms basically disappeared. Examination results: ECG ST-T improved in 20 days, blood and urine Rt was normal. At 40 days, the ECG was almost normal, and blood and urine were normal.
  • Coronary heart disease 30 cases 10 cases markedly effective, accounting for 33.3%
  • Case source All patients with confirmed arteriosclerosis in the outpatient department.
  • Clinical effect grade standard (The therapeutic effect of the treatment device is divided into four levels according to cure, marked effect, effective and ineffective, and other instruments refer to implementation)
  • u Symptoms and electrocardiograms have improved. Most patients have symptoms such as chest tightness, palpitations, precordial pain, and generalized weakness, and the ECG has improved significantly. All patients had improved arteriosclerosis by heart and together. Most patients had decreased blood lipids and blood sugar levels. Some of them have poor circulation in the distal end, and both lower limbs have been cold. Although they wear this shoe in winter, they feel consciously warm and have a comfortable foot.
  • Type of disease Chronic rheumatoid arthritis
  • Number of cases A total of 30 cases, including 12 males and 18 females. The age ranged from 19 to 70 years old, 3 cases were milder, 25 cases were moderate, and 2 cases were heavier.
  • Patient Source Outpatients and inpatients were observed.
  • the patient's condition analysis has the following characteristics:
  • Clinical effect grade standard (The therapeutic effect of the treatment device is divided into four levels according to cure, marked effect, effective and ineffective, and other instruments refer to implementation)
  • the patient is chronic arthritis, blood Rt, urine Rt and erythrocyte sedimentation, and other major abnormalities, but repeated pains as the weather changes, and the treatment results are as described above.
  • the total effective rate is 90%
  • Clinical Trial Conclusion Clinical observation of 30 patients: The shoe is considered to have a good therapeutic effect on "chronic rheumatoid arthritis”. After more than 40 days and 2 courses of treatment, the total effective rate was 90%:
  • Number of cases A total of 30 cases, including 15 males and 15 females. There were 22 cases of 3040 years old, 3 cases of 41-50 years old, 4 cases of 51-60 years old, and 1 case of 60 years old and older.
  • Patient Source All cases were selected from patients with good compliance in the outpatient setting.
  • Clinical effect grade standard (The therapeutic effect of the treatment device is divided into four levels according to cure, marked effect, effective and ineffective, and other instruments refer to implementation)
  • Typical case Patient Zhou Yujuan, female, 31 years old, Hohhot Hui District Law Firm. History: After 3 years of childbirth, the child suffered from lumbar sleep, fatigue, weak waist and knees, sweating when doing some light work, feeling weak, and increased vaginal discharge after menstruation. Frequent repetitive, mild and mild symptoms, especially when the fatigue and mood are not good. After using the shoes, the symptoms of waist, fatigue, weak waist, sweating, and leucorrhea were alleviated. After one month of use, the condition was basically stable, and the spirit and physical strength improved.
  • Number of cases A total of 30 cases, including 18 males and 12 females. Ages range from 22-74 years old. Six patients were milder, 18 were moderate, and 6 were heavier.
  • Patient source Mainly outpatients.
  • the patient's condition analysis has the following characteristics:
  • Clinical effect grade standard (The therapeutic effect of the treatment device is divided into four levels according to cure, marked effect, effective and ineffective, and other instruments refer to implementation)
  • Type of disease Chronic bronchitis
  • Number of cases A total of 60 cases were divided into observation group 30 cases and control group 30 cases. There were 20 males and 10 females in the observation group, 16 males and 14 females in the control group. The observation group was 28-67 years old, with an average of 48.5 ⁇ 9.7 years. The age of the control group was 25-73 years old, with an average of 50.2 ⁇ 13.3 years.
  • Case source All cases were from the Department of Respiratory Diseases, Emergency Department, Geriatrics Self-diagnosis and Hospitalization in our hospital.
  • Clinical efficacy level criteria (The therapeutic device efficacy is divided into four levels according to cure, marked effect, effective, and ineffective, and other devices refer to implementation)
  • Cure Symptoms and signs disappeared after treatment, and physical and chemical indicators completely returned to normal.
  • Chronic bronchitis 30 cases in the observation group
  • Chronic bronchitis 30 cases in the control group
  • a control group was specially designed.
  • the control group and the observation group were treated with the same drug, and the observation group was added with the shoes, and the other conditions were completely the same.
  • the two groups were randomized, and the two groups were well comparable in terms of age, gender and condition. The results of solid clinical research are more objective and reliable.
  • the shoes have certain auxiliary therapeutic effects on lung spleen and kidney deficiency type and kidney incontinence type chronic bronchitis.
  • the shoe has obvious foot insulation and improved peripheral circulation, which may be helpful for promoting the operation of the gas and adjusting the balance of yin and yang.
  • Cure Symptoms and signs disappear or return to normal after treatment. Muscle strength reached 5 or above.
  • the shoe has more obvious foot insulation and improved peripheral circulation efficiency, which may be beneficial to promote the body's operation through the gas, balance the yin and yang, adjust the body's viscera and blood, and thus promote rehabilitation.
  • 1 waist ⁇ ⁇ disc herniation 15 males, 15 females, the largest age is 68 years old, the minimum age is 25 years old, an average of 45.1 years old.
  • 2 neck push disease 16 males and 14 females, the maximum age is 68 years old, the minimum age is 34 years old, with an average of 46.7 years old.
  • 3 inflammation around the shoulder joint 15 males and 15 females, the maximum age is 77 years old, the minimum age is 32 years old, with an average of 50.1 years old.
  • Patient source 3 cases 90 patients were observed in the outpatient department.
  • Case analysis 90 patients were from cities and mountainous areas in Inner Mongolia. After wearing the shoes, basically no other treatment was used. After 2 courses of treatment, the symptoms of most patients disappeared and relieved to varying degrees.
  • Clinical effect level criteria (The therapeutic device efficacy is divided into four levels according to cure, marked effect, effective, and ineffective, and other instruments are referenced for execution)
  • Typical cases 90 patients in 3 groups of this group, most of the patients with this therapy have improved symptoms and signs, but some patients have particularly obvious effects.
  • Sun Chunxian female, 37 years old suffering from inflammation around the shoulders, first felt the fever of both lower limbs after wearing shoes, the symptoms were obviously relieved after 3 days, and the symptoms of both shoulders disappeared after 10 days.
  • Lu Minggui male, 47 years old, Mi Qingkun, female 42 years old, all suffering from neck push. After wearing shoes, first feel the neck activity is flexible, 10 ⁇ 14 days all symptoms disappear, and some patients have the same Reaction, in short, some patients are particularly sensitive to the shoes, and the curative effect is remarkable.
  • the total effective rate is 80%
  • the total efficiency is 86%
  • the total effective rate is 90%

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

药疗鞋 技术领域
本发明涉及一种药疗鞋, 特别涉及皮鞋、棉鞋、 凉鞋、拖鞋以及各类鞋类。 背景技术
随着社会飞速发展, 人们的生活节奏也越来越快, 工作强度加大, 导致能 够用来锻炼身体的时间越来越少, 常年累积下来, 容易引发各种慢性病症。 因 此, 现有技术提供了各种药疗鞋, 期望能够为了改善人们的健康状况, 预防各 种慢性疾病。
但是, 现有的药疗鞋仅仅是简单的药与鞋体的组合, 药的设置位置、 设 置方式以及药的组分等都没有经过精细的考究, 难以达到预期效果。 发明内容
针对现有技术的不足, 本发明的目的在于: 提供一种药疗鞋, 在不影响人们曰 常工作的前提下, 促进人体足部的血液循环通畅旺盛, 可对各类慢性疾病起到 治疗和预防的作用。
为实现上述目的, 本发明采用的技术方案是:
一种药疗鞋, 其特征在于: 所述鞋底的鞋垫设有至少一个凹陷槽, 四陷槽内分 别放置任意数量、 任意规格的容器, 容器底部设有容器底托, 容器设有孔洞或容 器用布料覆盖, 供药物从所述的孔洞或布料处挥发出来, 容器内盛装具有药疗 作用的药物组合物, 所述的药物组合物至少包括选自粉剂药粉、 液体药剂、 挥发油类组合物中的一种。
较佳的技术方案中: 所述的容器是由带有内卡边或者带有内圆弧形卡边并带 有孔洞的上盖, 以及外沿带有外卡边或者带有外圆弧形卡边的底盒上下扣合而 成。
较佳的技术方案中: 所迷的容器包括带有内卡边或者带有内圓弧形卡边的扣环, 以及外沿带有外卡边或者带有外圆弧形卡边的底盒上下扣合而成, 所述的扣环 将至少 1层布料卡合在底盒的开口处。
较佳的技术方案中: 所述的容器底部设有至少一个容器底托, 以防止容器 被足部踩塌陷后离位或者错位,容器底托设置在鞋底安放容器的相应位置的下 部, 容器底托的上端达到鞋垫的下表面为宜, 容器底托的厚度可随着鞋底厚度 的变化而变化, 所述的容器和容器底托可采用任意材料制成圓形、 方形、 异形 或者任意形状任意体积任意规格。
较佳的技术方案中: 所述的粉剂药粉、 液体药剂均包括由单一的 1 种药 物冰片制得, 上述的水片的重量配比为 1 - 9重量份。
较佳的技术方案中: 所述的粉剂药粉、 液体药剂均包括由 1种药物冰片, 另外再加入包括丁香、 白豆蔻、 当归、 莪术、 白芷、 樟木等药物进行组合后制得, 或者由上述的任何 1种药物与水片单独的配伍后制得,上述的冰片、丁香、白豆蔻、 当归、 莪术、 白芷、 樟木等原料药材的重量配比分别为 1 - 9重量份。
较佳的技术方案中: 所述的粉剂药粉、 液体药剂的制备方法包括以下步骤:
①称取原料: 按照成分重量比称取各原料;
②将上述各原料进行精细歸选、 研细成粉和过薛, 即得各原料药粉;
③将每 1种原料药粉内单独的加入冰片, 即得所述的单味的粉剂药粉, 若需混合的粉剂药粉时, 将单味的粉剂药粉相互混合后即得。
④将上迷的粉剂药粉除冰片外各自分别在含有水乙酸或者冰醋酸的水溶液中进 行浸泡, 再经单独渗漉提取即得其余各原料的提取原液, 然后将研细成粉的冰片 加入到单独的提取原液中, 即得所述的单独的液体药剂, 若需混合的液体药 剂时, 将单味的液体药剂相互混合后即得。
较佳的技术方案中:所述的挥发油类组合物的成分包括: 丁香油、丁香酚、 丁香罗勒油、 桉叶油和冰片, 它们的重量配比分别为 1 - 9重量份。
较佳的技术方案中: 所述的挥发油类组合物的制备方法包括以下步骤:
①称取原料: 按照成分重量比称取上述各挥发油原料;
②将上述每 1种挥发油原料内单独的加入冰片, 即得所述的单味挥发油 类组合物,若需混合的挥发油类组合物时,将单味的挥发油类组合物相互混合后即得。
较佳的技术方案中: 所述的液体药剂、 挥发油类组合物 2种剂型可以混合 后滴入所述的空的容器中使用; 也可以将所述的液体药剂、 挥发油类组合物 2 种剂型混合后滴入所述的装有 ^^剂药粉的容器中使用; 还可以将所述的液体药 剂、挥发油类组合物 2种剂型各自单独的滴入所述的装有粉剂药粉的容器中使 用。
与现有技术相比较, 本发明具有的有益效果是:
1、 粉剂药粉、 液体药剂和挥发油类组合物均放置在容器内, 容器具有设有孔 洞的上盖或者设有布料, 使得粉剂药粉、 液体药剂和挥发油类组合物可以得到 挥发。
2、 本发明的粉剂药粉、 液体药剂和挥发油类组合物可以各自单独使用发挥药 疗的作用, 还可以组合使用发挥更大更好的药疗作用。 附图说明
图 1是药疗鞋的立体图;
图 2是鞋垫的立体图;
图 3是鞋垫的剖面图;
图 4是鞋垫安放容器的立体图;
图 5是鞋垫安放容器的剖面图;
图 6是鞋底容器底托的立体图;
图 7是鞋底容器底托的剖面图;
图 8、 图 9分别是容器的一种实施方式的组合立体图和分解立体图; 图 10、 图 1 1分别是容器的另一种实施方式的组合立体图和分解立体图; 图 12、 图 13分别是容器的再一种实施方式的组合立体图和分解立体图; 图 14、 图 15分别是容器的还一种实施方式的组合立体图和分解立体图。 具体实施方式
为了使本发明的形状、 构造以及特点能够更好地被理解, 以下将通过较 佳实施例并结合附图对本发明进行详细说明。 为了使本发明的结构更加清晰, 所述的附图有可能在绘制过程中改变了实际的比例关系, 这不应当被理解为对 本专利申请的限定。
本发明是将药疗功能的理疔机理及结构设计, 设置于单鞋、 棉鞋、 凉鞋、 拖 鞋以及各类鞋类中。
如图 1〜图 7所示, 是药疗鞋的立体图, 所述的药疗鞋包括鞋垫 1 1, 鞋垫 1 1设置至少一个凹陷槽 12, 凹陷槽 12内设置容器 13, 容器 13底部的鞋底 14 对应凹陷槽 12的位置设置有容器底托 15。
如图 2、 图 3所示, 是鞋垫 1 1的立体图、 剖面图, 所述的鞋垫 1 1设置 凹陷槽 12。
如图 4、 图 5所示, 是安放了容器 13的鞋垫 1 1的立体图、 剖面图, 所述鞋垫 11的凹陷槽 12内设置容器 13。
如图 6、 图 7所示, 是药疗鞋的鞋底 14容器底托 15立体图、 剖面图, 所述的鞋底 14设置容器底托 15, 容器底托 15设置于鞋垫 11安放容器 13的相 应位置的下部, 以防止容器 13被足部踩塌陷后离位或者错位。 容器底托 15的 上端达到鞋垫 11的下表面为宜, 容器底托 15的厚度可随着鞋底 14厚度的变化而 变化, 容器 13和容器底托 15可采用任意材料制成圆形、 方形、 异形或者任意 形状任意体积任意规格。
如图 8、 图 9所示, 所述的容器 13是由带有内卡边以及带有孔洞的上盖 131和外 沿带有外卡边的底盒 132上下扣合而成。
如图 10、 图 11所示, 所述的容器 13包括带有内卡边的扣环 133和外沿带有 外卡边的底盒 132, 所述的扣环 133将至少一层布料 137卡合在底盒 132的开口处。
如图 12、 图 13所示, 所述的容器 13是由带有内圆弧形卡边以及带有孔洞的上 盖 134和带有外圆弧形卡边的底盒 135上下扣合而成。
如图 14、 图 15所示, 所述的容器 13包括带有内圆弧形卡边的扣环 133和带 有外圆弧形卡边的底盒 132, 所述的扣环 133将至少一层布料 137卡合在底盒 132的开 口处。
容器 13设有孔洞或容器 13用布料 137覆盖, 可供药物从所述的孔洞或布 料 137处挥发出来, 容器 13内盛装具有药疗作用的药物组合物, 所述的药物组 合物至少包括: 粉剂药粉、 液体药剂与挥发油类组合物的其中一种。
其中: 所述的粉剂药粉、 液体药剂的成分可以仅包括水片。
则, 制备所述的粉剂药粉的制备方法是: 将冰片进行精细筛选、 研细成粉 和过筛, 即得所述的粉剂药粉。
且, 制备所述的液体药剂的制备方法是: 将冰片研细成粉, 然后放入含 有冰乙酸或者冰醋酸的水溶液中, 即得所述的液体药剂。
当然, 所述的粉剂药粉、 液体药剂的成分还可以包含其它辅助成分, 例如, 包括丁备和水片, 各原料分别占 1 ~ 9重量份。
以下介绍所述的粉剂药粉的制备方法, 其包括以下步骤:
①称取原料: 按照成分重量比称取各原料, 例如: 称取丁香 1重量份和 水片 9重量份或者是丁香 9重量份和水片 1重量份。
②将上述各原料分别进行精细薛选、 研细成粉和过 , 即得各原料的药粉;
③将所有原料的药粉均勾混合, 即得所述的粉剂药粉。 以下介绍所述的液体药剂的制备方法, 其包括以下步骤:
①称取原料: 按照成分重量比称取各原料; 例如: 称取丁香 1重量份和 冰片 9重量份或者是丁香 9重量份和水片 1重量份。
②将原料中的丁香和冰片单独研细成粉;
③将原料中的丁香粉在含有水乙酸或者冰醋酸的水溶液中浸泡, 渗漉提取即 得所述的提取原液;
④将研细成粉的水片加入到混合好的提取原液中, 即得所述的液体药剂。 在较佳的实施方式中: 为了制取所述粉剂药粉、 液体药剂, 还可以增加其 它原料成分, 增加后的原料成分除水片外还包括: 丁香、 白豆蔻、 当归、 莪 术、 白芷、 樟木, 各原料分别为 1 - 9重量份。
以下介绍所述的粉剂药粉的制备方法, 其包括以下步骤:
①称取原料: 按照成分重量比称取各原料, 例如: 称取冰片 9重量份、 丁香 1重量份、 白豆蔻 1重量份、 当归 1重量份、 莪术 1重量份、 白芷 1重量 份、 樟木 1重量份, 或者冰片 1重量份、 丁香 9重量份、 白豆蔻 9重量份、 当归 9重量份、 莪术 9重量份、 白芷 9重量份、 樟木 9重量份。
②将上述各原料进行精细 选、 研细成粉和过薛, 即得各原料药粉;
③将每 1种原料药粉内单独的加入冰片, 即得所述的单味的粉剂药粉, 若需混合的粉剂药粉时, 将单味的粉剂药粉相互混合后即得。
以下介绍所述的液体药剂的制备方法, 其包括以下步骤:
①称取原料: 按照成分重量比称取各原料, 例如: 称取冰片 9重量份、 丁香 1重量份、 白豆蔻 1重量份、 当归 1重量份、 莪术 1重量份、 白芷 1重量 份、 樟木 1重量份, 或者水片 1重量份、 丁香 9重量份、 白豆蔻 9重量份、 当归 9重量份、 莪术 9重量份、 白芷 9重量份、 樟木 9重量份。
②将上述各原料进行精细 选、 研细成粉和过薛, 即得各原料药粉;
③将每 1种原料药粉内单独的加入冰片, 即得所述的单味的粉剂药粉, 若需混合的粉剂药粉时, 将单味的粉剂药粉相互混合后即得。
④将上述的粉剂药粉除冰片外各自分别在含有冰乙酸或者水醋酸的水溶液中进 行浸泡, 再经单独渗漉提取即得其余各原料的提取原液, 然后将研细成粉的水片 加入到单独的提取原液中, 即得所述的单独的液体药剂, 若需混合的液体药 剂时, 将单味的液体药剂相互混合后即得。
至于所述的挥发油类组合物, 其成分包括: 冰片、 丁香油、 丁香酚、 丁香罗勒油、 桉叶油, 各原料占 1 ~ 9重量份。
①称取原料: 按照成分重量比称取各原料; 例如: 称取水片 9重量份、 丁香油 1 重量份、 丁香罗勒油 1重量份、 丁香酚 1 重量份、 桉叶油 1 重量 份或者水片 1重量份、 丁香油 9重量份、 丁香罗勒油 9重量份、 丁香酚 9重量 份、 桉叶油 9重量份。
②将冰片单独研细成粉;
③将上述每 1种挥发油原料内单独的加入水片 , 即得所述的单味挥发油 类组合物,若需混合的挥发油类组合物时,将单味的挥发油类组合物相互混合后即得。
使用所述药疗鞋的时候, 可以将所述的液体药剂、 挥发油类组合物 2种剂 型混合后滴入空的容器中使用; 也可以将所述的液体药剂、 挥发油类组合物 2种 剂型各自单独滴入所述的装有粉剂药粉的容器中使用, 还可以将所述的液体 药剂、挥发油类组合物 2种剂型混合后滴入所述的装有粉剂药粉的容器中使用。
如上所述, 所述药疗鞋的鞋垫 11设置有盛放粉剂药粉、 液体药剂、 挥发油 类组合物的容器 13 , 容器 13 内的药物, 给穿用者的足部提供药疗, 其药物 的药理作用可通过足部透皮吸收, 活血通脉, 活跃细胞, 促进人体的血液循 环及微循环通畅旺盛, 对人体起到药疗和保健的作用。 适用于糖尿病及并发 症、 高血压、 冠心病、 心动过緩、 脑梗、 脑血栓、 脑溢血后遗症、 颈推病、 腰 推病、 肩周炎、 风湿、 类风湿性关节炎、 痛风、 股骨头坏死、 腰腿无力、 失 眠、 便秘、 前列腺增生、 支气管炎、 过敏性哮喘、 过敏性鼻炎、 神经性皮炎、 湿疹、 药疹、 贫血、 胃炎、 肠炎、 肾脏疾病、 妇科疾病等缺血性慢性疾病, 可数病同治, 康复率高, 安全实用, 简便易行。
上述内容仅仅是提供一个优选实施例, 实际上还可以作出许多小的调整, 例 如: .
鞋垫 1 1上的凹陷槽 12及容器 13、 鞋底 14上的容器底托 15, 可以采 用任意材料设计为圆形、 方形、 异形或者任意形状任意体积任意规格, 由于其结 构变化简单, 容易理解, 故不予图示。
以上实施例并不能完全概括本发明的所有实施方式, 本领域技术人员在 其基础上, 不经创造性劳动就可以进行多种改动或者组合, 例如将本发明技术 方面的设计及结构, 重新调整组合设置安放于单鞋、 棉鞋、 凉鞋、 拖鞋以及各类 鞋类中, 即可形成各类型的药疗鞋, 但这应该属于本发明的保护范围。
以上说明对本发明而言只是说明性的, 而非限制性的, 本领域普通技术人 员理解, 在不脱离权利要求所限定的精神和范围的情况下, 可作出许多修改、 变化或者等效, 但都将落入于本发明的保护范围之内,
最后, 结合现代医疗理论, 说明本发明的有益效果:
生物电流充足时, 骨密度增高, 骨髓干细胞的造血功能得到增强:
骨酪是人体的支架, 骨髓干细胞是生产红细胞、 白细胞、 血小板的造血工厂。 穿用所述鞋之后, 即可给穿用者的足部提供药疗的措施, 其药物的药理作 用可通过足部透皮吸收, 活血通脉, 活跃细胞, 促进人体的血液循环及微循环 通畅旺盛, 对人体起到药疗的作用。 这时候, 红细胞在药疗的作用下就会更加兴 奋活跃, 红细胞就可得到生物电流的充足补充, 携带氧气及曲卷变形, 向前螺旋运动 的速度加快。 红细胞就会很快的将骨骼及骨髓膜内的毛细血管床得到疏通, 使骨 骼及骨髓膜内的血液循环通畅旺盛。
因而, 可使骨骼及骨髓膜的微循环障碍及缺血、 缺氧的问题基本消除。
当骨骼的血液的循环通畅旺盛后, 骨骼即可从血液中得到骨胶原纤维束 和维生素八、 D、 C的大量的供应, 使骨基质的形成得到保证。
这时候, 血液中的类骨质及 4弓盐即可在骨基质上得到沉积, 使骨密度得到增高, 腰腿结实, 上楼或走长路, 不疲惫乏力, 不腰酸腿痛, 并使得中老年人因缺钙、 缺氧, 而经常性发生的腿脚抽筋的问题也得到消除。
当红细胞在对骨骼及骨髓膜内的毛细血管床进行疏通的同时, 可将自 身所携带的生物电流, 传递补充给骨髓干细胞即红骨髓。
这时候, 骨髓干细胞就会得到生物电流的充足补充, 以及血液和氧气的充足供 应。 因而, 骨髓干细胞的造血功能就可得到增强, 可及时的生成成熟的红细胞、 白 细胞、 血小板。 并且, 可使这些血细胞的生成数量保持在正常的数值内。
因而, 穿用所述鞋之后, 特别是可使中老年人的骨骼及骨髓干细胞的造血生 理机能长期的保持在活跃旺盛的状态中。 所以, 就可使穿用所述鞋之后的中老年 人的各类炎症肿痛得到消除, 不腰酸腿痛, 腰腿有力, 精力充沛, 体质增强, 免疫力提高, 基本不感冒。 而且, 穿用所述鞋之后, 还可益寿延年, 延緩衰老。
为了验证本发明药疗鞋的治疗和保健功效, 申请人提供一份本发明在内蒙 古自治区各医院的临床试用结果如下:
一、 内蒙古自治区医院临床试用
病种: 高血压
起止时间: 1995年 12月 5 日一1996年 1月 15 曰。 病例数: 共 30例, 男 20例, 女 10例, 年龄 35-65岁。
病人来源: 全部病例均为门诊已确诊的高血压病人。 观察期内除 I期高血 压停用降压药物外, II期高血压病人均继续用药物, 定期测血压, 每日 2次, 在 观察的过程中, 血压下降均减服降压药物或停服降压药物。 30例中有 3例 m期 高血压。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其他器械参照执行)
1、显效: ①舒张压下降 1.33kPa ( 10mmHg )或以上。②舒张压虽未降至正常, 但已下降 2.67kPa或以上者。
2、 有效: ①舒张压下降不及 1.33kPa, 但已达到正常范围者。 ②舒张压 较治疗前下降 1.33— 2.53kPa, 但未达到正常范围者。 ③收缩压较治疗前下降 4.00kPa以上者。
3、 无效: 未达以上标准者。
典型病例: 患者韩忠昌, 男, 年龄 58岁, 体重 76kg, 内蒙外贸干部, 诊断 高血压病 6 年, 一直间断服用降压药物治疗。 症状: 头暈、 胸闷, 血压最高达 180/120mmHg。 患者 1995年 12月 5 日开始穿所述鞋, 第 2天血压降至正常(因 家人里有从事医生工作, 每日测三、 四次血压) , 停穿鞋 3 天后, 血压稍回升, 又穿鞋并停服降压药物。 自述, 头晕、 胸闷症状明显改善。 心电图检查 S_T段下移 较前改善。 血、 尿 Rt正常。
临床效果统计:
高血压症 I期: 9例
显效 0例 占 0%
有效 7例 占 77.8%
无效 2例 占 22.2%
高血压症 II期: 18例
显效 2例 占 11.1%
有效 14例 占 77.8%
无效 2例 占 11.1%
高血压症 ΠΙ期: 3例
显效 1例 占 33.3%
有效 2例 占 66.7% 无效 0例 占 0%
总病例数: 30例 总有效率 为 86.7%
显效 3例 占 10%
有效 23例 占 76.7%
无效 4例 占 13.3%
临床试验结论: 经 30例高血压病人的临床观察所述鞋对改善高血压病的症状 及降压有一定疗效, 在一部分轻度高血压病人不服降压药, 可降至正常, 个别 中度高血压因血压下降较低而停服降压药物, 并对高血压症常见的头晕、 头痛改善 较明显。
二、 内蒙古自治区医院临床试用
病种: 糖尿病
起止时间: 1995年 12月 5日一 1996年 1月 15 日, 2个疗程, 共 40天。 病例数:糖尿病 30例(胰岛素依赖型 <IDDM>5例,胰岛素非依赖型<]^1001^>25 例) , 男 15例, 女 15例, 最大年龄 69岁, 最小年龄 25岁。
病人来源: 30例患者均符合 1980年世界卫生组织 《糖尿病专家委员会》制 定的糖尿病诊断标准而确诊的糖尿病。 来自呼市地区的门诊病人, 并能与医生 配合接受走访者。 30例中, 轻型 25例, 中型 5例。 轻型 25例中, 5例靠饮食 控制, 20例服用口服降糖药物。 中型 5例接受胰岛素治疗, 但 30例病人均能参 加正常工作和劳动, 无严重急慢性合并症。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其他器械参照执行)
1、 显效: 实验室检测血糖, 尿糖明显降低, 其他症状体征有明显改善。
2、 有效: 实验室检测血糖, 尿糖有所降低, 其他症状体征有所改善。
3、 无效: 实验室检测血糖, 尿糖无变化, 其他症状体征也无明显改善。 典型病例: 患者李锁怀, 男, 58岁, 体重 75kg, 多饮、 多尿、 口渴、 消瘦
10余月。 在我院门诊确诊糖尿病, 用饮食控制及少量降糖药物治疗。 临床症状 及血糖、 尿糖控制仍不能令人满意, 试穿用所述鞋, 在穿鞋前将口服降糖药物 停用, 化验血糖 10.8mmol/L, 自诉口渴、 乏力、 多饮, 穿鞋第一个疗程后, 化验血糖 7.1 mmol/L, 尿糖 (- ) 以上自觉症状好转, 第 2个疗程后血糖下降 到正常范围 (6.15 mmol/L )全身自我感觉良好, 非常激动的告诉我们这种鞋 值得推广, 穿起来特别舒适, 还要为我们做宣传。 临床效果统计:
糖尿病: 30例
显效 12例 占 40%
有效 15例 占 50%
无效 3例 占 10%
总有效率: 90%
临床试用结论:
1、 经过 30例患者的临床观察, 认为所述鞋对糖尿病确有一定的治疗作用。 特别是对轻型糖尿病更适合, 但我们一定提醒患者偏面认为穿鞋后就不要别的治 疗是不对的。 因为糖尿病的现代治疗是综合性的。
.2、所述鞋不仅有治疗作用, 而且是糖尿病人很好的保健用品, 穿起来舒适、 柔软, 无痛感, 对糖尿病人足起了保护性的作用。
3、 所述鞋在使用过程中无不良反应。
三、 内蒙古自治区医院临床试用
病种: 冠心病
病例数: 总数为 30例, 其中男 20例, 女 10例, 年龄为 36~65岁。 病情较轻者 为 10例, 中度 19例, 重度 1例。
病人来源: 均为既往诊断为冠心病的门诊病人。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划 分, 其他器械参照执行)
1、 显效: 临床症状改善 80%, 或心电图 S-T段恢复 0.03mv, 下波倒置较前度浅。
2、 有效: 临床症状改善 60%。
3、 无效: 临床症状改善低于 60%, 心电图无改善。
典型病例: 患者安治国, 男, 51岁, 体重 70.5kg, 胸闷、 头晕、 心前区痛乏 力 3年余, 经心脏 "B"超心电图诊冠心病,一直服用扩冠抗凝药物治疗, 12月 5 日 起穿所述鞋, 并同时服用扩冠抗凝药物, 3天后胸闷减轻, 1周后胸闷、 心悸、 心前区 痛明显减轻, 20天后心电图大致正常, 减服扩冠抗凝药物 40天后心电图基本正 常, 其它症状基本消失。 检查结果: 20天时心电图 ST-T较前改善, 血、 尿 Rt 正常。 40天时心电图大致正常, 血、 尿 Rt正常。
临床效果统计:
冠心病: 30例 显效 10例 占 33.3%
有效 17例 占 56.7%
无效 3例 占 10%
总有效率: 为 90%
临床试用结论: 经 30例冠心病的临床观察所述鞋对改善冠心病的症状及心肌缺 血有一定疗效, 大多数患者自觉胸闷减轻明显, 全身乏力等症状减轻明显, 有一 部分人可减少扩冠抗凝药物的剂量, 有一部分人由于末梢循环较差双下肢一直 发凉, 但虽在冬季, 穿所述鞋后自觉脚部发热, 足部舒适感。 所见患者有少数出 血现象, 考虑此鞋有抗凝作用建议出血性疾病患者不能使用。
四、 内蒙古自治区医院临床试用
病种: 动脉硬化
起止时间: 1996年 12月 1 日 -1996年 12月 31 日。
病例数: 共 30例, 男 25例, 女 5例。 年龄 40-70岁。
病例来源: 均为门诊已确诊动脉硬化的病人。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其他器械参照执行)
1、 显效: 心电图恢复正常, 各种动脉硬化引起的症状消失。
2、 有效: 心电图有所改善, 动脉硬化引起的症状大多数明显减轻。
3、 无效: 无任何改善。
典型病例: 患者安治国, 男, 52岁, 体重 65.5kg, 胸闷、 头晕、 心前区痛 3年 余, 经血化验血脂增高, 血粘度增高, 心电图 T波改变, 心脏彩超, 主动脉硬化, 一直服用降脂、 抗凝等药物治疗。 12 月初期穿所述鞋同时服用上述药物, 但较前 减量, 20天胸闷心前区疼痛减轻, 40天化验心电图、心脏彩超检查较前明显改善, 主动脉硬化基本消失。
临床效杲统计:
动脉硬化: 30例
显效 4例 占 13%
有效 23例 占 77%
无效 3例 占 10%
总有效率: 为 90%
临床试用结论: 经 30例动脉硬化的临床观察, 所述鞋对改善动脉硬化
u 的症状及心电图有一定改善, 大多数病人自觉胸闷、 心悸、 心前区痛、 全身乏 力等症状明显减轻, 心电图有明显改善。 各例病人经心脏及一起检查动脉硬化有 所改善, 大多数病人血脂、 血糖度有所下降。 有一部分由于末梢循环较差, 双下 肢一直发凉, 虽在冬季穿此鞋后自觉脚步发热, 足部舒适感。
五、 内蒙古中蒙医院临床试用
病种: 慢性风湿性关节炎
起止时间: 1995年 12月 8日 -1996年 1月 18日 合计: 41天
病例数: 共 30例, 其中男 12例, 女 18例。 年龄在 19-70岁不等, 病情较轻 者 3例, 中等者 25例, 较重者 2例。
病人来源: 以门诊患者和住院患者为观察对象。
本组病人病情分析, 有以下特点:
1、 80%以上的患者为慢性风湿性关节炎, 每到冬季或变天时疼痛加重, 而其化 验析查无大的改变, 大都在正常范围。
2、 经反复治疗的历史。 曾加服中药、 西药和部分蒙药等。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其他器械参照执行)
1、 显效: 慢性患者以临床症状的改善为主: 改善 75%-80%为显效。 急性风湿 性关节炎(部分) 除了有临床症状改变, 血沉抗 "0"转正常。
2、 有效: 慢性风湿性关节炎, 临床症状改善 60%以上。 急性病人有血沉抗" 0" 的改变。
3、 无效: 慢性风湿性关节炎患者临床症状改善在 50%以下者。
典型病例: 患者敖占元, 男, 56岁, 65kg。 患者在 10年前受寒而患有慢性风湿 性关节炎,十年来服了很多治疗风湿性关节炎的西药、蒙药和中药,但终有反复现象。 今年 12月到该院门诊治疗, 在医师的指导下试穿所述鞋, 十多天以后感觉很好。 表 现为关节开始发热, 脚面温暖, 不因变天而疼痛发作, 起到了较好的治疗效果。
患者属于慢性关节炎, 血 Rt、 尿 Rt和血沉等检查及有大的异常, 只是随天气 变化而有反复疼痛等, 其治疗结果如上所述。
临床效果统计:
病例数: 30例
显效 6例 占 20%
有效 21例 占 70% 无效 3例 占 10%
总有效率 为 90%
临床试用结论: 经 30例患者的临床观察:认为该鞋对"慢性风湿性关节炎" 有良好的治疗作用。 经 40余天、 2个疗程的观察, 其总有效率为 90%:
其特点为, 对于下肢发冷、 关节疼痛等改善明显, 而且快, 有温暖、 舒适, 适合保健与治疗的双重功效。
六、 内蒙古中蒙医院临床试用
病种: 肾虚
起止时间: 1995年 12月 8日 -1996年 1月 18曰。
病例数: 共 30例, 其中男 15例, 女 15例。 年龄在 3040岁的 22例, 41-50岁的 3例, 51-60岁的 4例, 60岁以上的 1例。
病人来源: 全部病例均选自门诊顺从性良好的患者。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其他器械参照执行)
1、 显效: 临床症状及体征的 80%以上, 达到正常者为显效。
2、 有效: 临床症状及体征的 60-70%以上, 达到正常者为显效。
3、 无效: 50%以下为无效。
典型病例: 患者周玉娟, 女, 31 岁, 呼市回民区律师事务所。 病史: 该患 3 年前因分娩后, 引起腰困、 乏力、 腰膝酸软, 干一些轻活时出虚汗, 身体感觉乏 力, 月经后白带增多。 经常性的反复, 症状时重时轻, 尤其劳累及情绪不佳时症状体征 加重。 用所述鞋后, 腰困、 乏力、 腰膝酸软、 出虚汗、 白带多等症状明显的减轻, 经 一个月的使用后, 病情基本稳定, 已精神, 体力有了好转。
临床效果统计:
肾虛: 30例
显效 5例 占 16%
有效 23例 占 76.6%
无效 2例 占 6%
总有效率: 为 93.2%
临床试验结论:肾虚引起的各种症状是中壮年人的常见病,临床上较为多见。 所述鞋正是根据中医经典理论结合现代技术研制而成, 其治疗原理是使中药通 过穴位导入人体经络, 以改善肾虚等引起的各种症状。 在细观察证明所述鞋对 肾虚引起的各种腰痛、 虚寒、 腰推骨质增生的总有效率为 93.2%。 对腰困、 乏力、 腰膝酸软、 白带多等症状具有明显改善作用。 它具有疗效确切, 作用快, 无副、 毒作用, 是使用方便, 操作简单等优点, 很值得向社会推广应用。
七、 内蒙古中蒙医院临床试用
病种: 神经官能症
起止时间: 1995年 12月 8日 -1996年 3月 18日。
病例数: 共 30例, 其中男性 18例, 女性 12例。 年龄 22-74岁不等。 病 情较轻者 6例, 中等者 18例, 较重者 6例。
病人来源: 主要以门诊患者为主。
本组病人病情分析有以下特点:
• 1、 部分青年, 特别是大中专学生和脑力劳动者长年精神紧张而出现神经官能 症的症
2、部分患者属年迈体弱、 生活困难、 孩子就业难等导致的现神经官能症、 神经衰弱的病态。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其他器械参照执行)
1、 显效: 80%临床症状改善者。
2、 有效: 60%以上的临床症状改善者。
3、 无效: 50%以上的临床症状无改善者。
典型病例: 患者贺永胜, 男, 54岁, 体重 82kg, 于 1995年 12月 9日来院就 诊, 诊断: 1、 神经衰弱, 2、 神经官能症。 主症为: 出现心慌、 心悸、 失眠、 多梦、 疲乏等临床症状 2年多, 加重 2个月。 体格检查: 血压: 130/90mmHg, 体 温 36。 ( 、 脉 76次 /分、 呼吸 19次 /分, 属肥胖型体型。 患者于就诊当日在我院大 夫的指导下试穿所述鞋而走, 第 5 天来院自述: 心慌、 心悸、 耳呜等症状开始 好转。 晚上睡眠开始加重, 继用 40余天, 治疗效果显著。 本组病人未做临床检 验。
临床效果统计:
神经官能症: 30例
显效 13例 占 43.3%
有效 15例 占 50%
无效 2例 占 6.7% 总有效率: 为 93.3%
临床试用结论: 经 30例患者近 40余天的临床观察,所述鞋对"神经官能症" 的各种临床症状有一定的治疗作用。 总有效率达 93.3%。 患者普通反映所述鞋 穿后足部温暖、 舒适, 使人的精神振奋, 不感觉困, 走路过多而感觉疲乏等。 而且, 未发现任何副作用。
八、 内蒙古中蒙医院临床试用
病种: 慢性支气管炎
起止时间: 1996年 12月 1 日一1997年 3月 28曰。
病例数: 共 60例, 分为观察组 30例和对照组 30例, 观察组男 20例, 女 10 例, 对照组男 16例, 女 14例。 观察组年龄 28— 67岁, 平均 48.5±9.7岁, 对 照组年龄 25— 73岁, 平均 50.2±13.3岁。
病例来源: 全部病例均来自我院呼吸病科、 急诊科、 老年病科自诊及住院病 例。
临床效杲等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其他器械参照执行)
1、 治愈: 治疗后症状和体征全部消失, 理化指标完全恢复正常。
2、 显效: 治疗后症状和体征改善 70%以上, 理化指标恢复 2/3以上者。
3、 有效: 治疗后症状和体征改善 30%以上, 理化指标恢复 1/3以上者。
4、 无效: 治疗后症状和体征无改善或改善不足 30%, 理化指标恢复不足 1/3 者。
典型病例: 患者杨玲, 男性, 58岁, 工作单位, 呼和浩特市郊区人大常委会, 电话: 6957140。 患者主症为咳嗽、 咯痰, 以晨起为著, 病程为 5年, 经内蒙古中 蒙医院 X光诊断为慢性支气管炎。患者自 97年 1月开始使用所述鞋治疗,疗程为 40 天。 患者穿鞋治疗期间同时口服头孢胶嚢 3T tid po, 共服 1周。 使用所述鞋及用药 1周后咳嗽、 咯痰量明显减少, 由原来每天晨起咯痰约 30mml减少为咯痰 1一 2 口痰, 治疗 40天后, 咳嗽、 咯痰症状消失, 经复查 X光片示较前明显吸收, 免 疫球蛋白也较治疗前有明显改变, 说明所述鞋配合药物治疗能提高机体免疫力, 改 善机体状态, 对慢性支气管炎有良好的辅助治疗作用。
临床效果统计:
慢性支气管炎: 观察组 30例
显效 5例 占 16.7% 有效 21例 占 70%
无效 4例 占 13.3%
总有效率: 为 86.7%
慢性支气管炎: 对照组 30例
显效 5例 占 16.7%
有效 20例 占 66.7%
无效 5例 占 16.7%
总有效率: 为 83.3%
临床试用结论:
1、 临床机理研究结论:
.①为了较客观的评价所述鞋对慢性支气管炎的治疗作用, 特设计了对照组。 对照组与观察组采用相同的药物治疗, 唯观察组加用所述鞋, 其余条件完全相 同。 2组采用随机化分组, 2组在年龄, 性别及病情等方面均有较好可比性。 固临床研究结果是较为客观和可靠的。
②临床资料表明, 治疗后观察组与对照组均获得一定疗效, 经综合疗效分析 2 组间显效率和总有效率均无统计学差异 (P 均 >0.05 ) , 说明其疗效主要来自于 药物作用。 但在减轻咳痰、 气喘、 心慌、 气短和哮鸣音方面观察组略优于对照 组, 但均未达到统计学差异 (P 均 >0.05 ) , 提示所述鞋只起到一定的辅助治 疗作用, 大多数患者 (70%以上) 穿该鞋后感到足部温暖、 舒适, 肢凉得到 改善, 提示该鞋有助于改善末梢循环。 临床研究表明, 该鞋对肝脾肾虚寒和肾 不纳气型慢性支气管炎具有一定的辅助改善某些症状和体征的作用。
2、 临床试用结论:
①综合疗效评价和所有观察指标, 观察组与对照之间均未见统计学差异。
②所述鞋对肺脾肾虚寒型和腎不纳气型慢性支气管炎具有一定的辅助治疗作 用。
③该鞋有较明显的足部保温和改善末梢循环作用, 可能对促进经气运行, 调 整阴阳平衡有所帮助。
④临床研究中未发现该鞋有任何不良反应。
九、 内蒙古中蒙医院临床试用
病种: 缺血性脑病后遗症
起止时间: 1996年 12月一 1997年 5月。 病例数: 将选择的 60例患者随机分为"药疗鞋组"和"对照组 "各 30例。 药疗鞋组: 男 24例, 女 6例, 平均年龄 55.9±9.0岁。 ( 40— 75岁) 对照组: 男 25例, 女 5例, 平均年龄 54.6±9.3岁。 (41一 73岁) 病例来源: 全部病例均来自我院脑病科、 急诊科和医务科所设的门诊和病 临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划 分, 其他器械参照执行)
1、 治愈: 治疗后症状和体征全部消失或恢复正常。 肌力达到 5级以上。
2、 显效: 治疗后症状和体征改善 70%以上, 肌力提高≥2级。
3、 有效: 治疗后症状和体征改善 30%以上, 肌力提高 1级。
4、 无效: 治疗后症状和体征无改善或改善不足 30%, 肌力未见提高。
典型病例: 患者许子珍, 男性, 75岁, 现住呼市旧城。 该患 1996年 10月突 发口埚、 舌僵、 右侧肢体运动不利, 经头颅 CT检查, 证实为腔隙性脑硬塞(同时 合并高血压病 ΠΙ期) , 应用中西医结合方法, 药物治疗 4个月, 仍有舌僵、 头痛、 头晕、 畏寒、 肢软无力, 穿用所述鞋治疗, 同时服用脑心通片, 每次 3粒, 日 3次, 脑复康片 0.8g, 每日 3次, 治疗 20天后, 舌僵、 头晕、 头痛减轻, 自觉足 下发热、 气血通畅、 肢体较前轻松, 右侧偏瘫患肢功能有所恢复。 内蒙古中蒙医 院: 张华。
临床效果统计:
缺血性脑病后遗症: 药疗鞋组 30例
显效 2例 占 6.7%
有效 23例 占 76.7%
无效 5例 占 16.7%
总有效率: 为 83.3%
缺血性脑病后遗症: 对照组 30例
显效 1例 占 3.3%
有效 21例 占 70%
无效 8例 占 26.7%
总有效率: 为 73.3%
临床试用结论:
1、所述鞋对缺血性脑病后遗症的临床显效率和总有效率分别为 6.7%和 83.3%, 略高于对照组(3.3%和 73.3% ), 但两组间无论统计学差异( P>0.05 )提示该鞋对 该后遗症残留的肢体运动障碍和感觉异常的恢复只有一定的促进康复作用。
2、该鞋有较明显的足部保温和改善末梢循环效能,可能对推动人体经气运行, 平衡阴阳, 调整人体脏腑气血, 从而促进康复有所裨益。
3、 临床试用期间, 所有病人均未发现明显不良反应, 提示该鞋具有较高的安全 性。
十、 内蒙古医学院第二附属医院临床试用
病种: 腰推间盘突出症、 颈推病和肩关节周围炎三种疾病。
起止时间: 1997年 1月 10日一 1997年 7月 10日。
病例数: 每个病种 30例, 计 90例病人。
①腰^^间盘突出症: 男 15例, 女 15例, 最大年龄 68岁, 最小年龄为 25岁, 平均 45.1岁。 ②颈推病: 男 16例, 女 14例, 最大年龄 68岁, 最小年龄为 34岁, 平均 46.7岁。 ③肩关节周围炎: 男 15例, 女 15例, 最大年龄 77岁, 最小年龄为 32岁, 平均 50.1岁。
病人来源: 3个病种 90例病人均为门诊的观察病人。
病例分析: 90例病人来自内蒙各地的城市和山区, 穿用所述鞋后基本不用其 他的治疗, 方法经 2个疗程的观察, 多数病人的症状都有不同程度的消失和緩解。
临床效果等级标准: (治疗器械疗效按治愈、 显效、 有效、 无效四级划分, 其 他器械参照执行)
本组临床效果标准, 3个病种均按显效、 有效和无效 3等级划分:
1、 腰推间盘突出症:
①显效: 症状和体征消失。
②有效: 症状和体征明显减轻。
③无效: 症状和体征无减轻。
2、 颈推病:
①显效: 症状和体征有明显改善或消失。
^有效: 症状和体征有所改善。
③无效: 症状和体征无明显改善
3、 肩关节周围炎:
①显效: 症状和体征消失。
②有效: 症状和体征明显改善。 ③无效: 症状和体征无变化。
典型病例: 本组 3个病种 90例病人, 用此疗法多数病人症状和体征都有所好 转, 但有的患者效果特别明显。 例如: 孙春先, 女, 37 岁患双肩周围炎, 穿鞋后首 先感觉双下肢发热, 3·^天后症状明显减轻, 10天后左右双肩症状全部消失。 还 有吕明贵, 男, 47岁, 米清坤, 女 42岁, 都患颈推病, 穿鞋后, 首先感到颈部活 动灵活自如, 10~14天症状全部消失, 还有些病人, 也有同样的反应, 总之, 有 的病人对所述鞋特别敏感, 疗效显著。
临床效果统计:
1、 腰推间盘突出症: 30例
显效 9例 占 30%
有效 15例 占 50%
无效 6例 占 20%
总有效率 为 80%
2、 颈推病: 30例
显效 13例 占 43%
有效 13例 占 43%
无效 4例 占 14%
总有效率 为 86%
3、 肩关节周围炎: 30例
显效 19例 占 63%
有效 8例 占 27%
无效 3例 占 10%
总有效率 为 90%
临床试用结论:
本组三个病种 90例病人, 经过两个疗程 6个月的临床试用观察。 我们认为, 此法筒单易行, 特别适合农村牧区, 不需任何医疗条件, 只穿一双鞋就起到治疗 和保健作用。 三个病种总有效率为 86%, 未发现副作用可以应用推广。

Claims

权利要求
1、 一种药疗鞋, 其特征在于: 所述鞋底的鞋垫设有至少一个凹陷槽, 凹陷槽内 分别放置任意数量、 任意规格的容器, 容器底部设有容器底托, 容器设有孔洞或 容器用布料覆盖, 供药物从所述的孔洞或布料处挥发出来, 容器内盛装具有药疗 作用的药物组合物, 所述的药物组合物至少包括选自粉剂药粉、 液体药剂、 挥发 油类组合物中的一种。
2、 根据权利要求 1所述的药疗鞋, 其特征在于: 所述的容器是由带有内卡边 或者带有内圆弧形卡边并带有孔洞的上盖, 以;^卜沿带有外卡边或者带有外圆弧形卡边 的底盒上下扣合而成。
3、 根据权利要求 1所述的药疗鞋, 其特征在于: 所述的容器包括带有内卡边 或者带有内圆弧形卡边的扣环, 以及外沿带有外卡边或者带有外圆弧形卡边的 底盒上下扣合而成, 所述的扣环将至少 1层布料卡合在底盒的开口处。
4、 根据权利要求 1所述的药疗鞋, 其特征在于: 所述的容器底部设有至少 一个容器底托, 以防止容器被足部踩塌陷后离位或者错位, 容器底托设置在鞋底 安放容器的相应位置的下部, 容器底托的上端达到鞋垫的下表面为宜, 容器底托 的厚度可随着鞋底厚度的变化而变化, 所述的容器和容器底托可采用任意材料 制成圆形、 方形、 异形或者任意形状任意体积任意规格。
5、 根据权利要求 1所述的药疗鞋, 其特征在于: 所述的粉剂药粉、 液体 药剂均包括由单一的 1种药物水片制得,上述的水片的重量配比为 1 ~ 9重量份。
6、 根据权利要求 1所述的药疗鞋, 其特征在于: 所述的粉剂药粉、 液体 药剂均包括由 1种药物冰片, 另外再加入包括丁香、 白豆蔻、 当归、 莪术、 白芷、 樟木等药物进行组合后制得, 或者由上述的任何 1种药物与水片单独的 配伍后制得, 上述的冰片、 丁香、 白豆蔻、 当归、 莪术、 白芷、 樟木等原料 药材的重量配比分别为 1 - 9重量份。
7、 根据权利要求 5、 6所述的药疗鞋, 其特征在于: 所述的粉剂药粉、 液体药剂的制备方法包括以下步骤:
①称取原料: 按照成分重量比称取各原料;
②将上述各原料进行精细 选、 研细成粉和过 , 即得各原料药粉;
③将每 1种原料药粉内单独的加入水片, 即得所述的单味的粉剂药粉, 若需混合的粉剂药粉时, 将单味的粉剂药粉相互混合后即得。
④将上述的粉剂药粉除水片外各自分别在含有冰乙酸或者冰醋酸的水溶液中 进行浸泡, 再经单独渗漉提取即得其余各原料的提取原液, 然后将研细成粉的 冰片加入到单独的提取原液中, 即得所述的单独的液体药剂, 若需混合的液体 药剂时, 将单味的液体药剂相互混合后即得。
8、 根据权利要求 1所述的药疗鞋, 其特征在于: 所述的挥发油类组合物的 成分包括: 丁香油、 丁香酚、 丁香罗勒油、 桉叶油和水片, 它们的重量配比 分别为 1 - 9重量份。
9、 根据权利要求 8所述的药疗鞋, 其特征在于: 所述的挥发油类组合物的 制备方法包括以下步骤:
①称取原料: 按照成分重量比称取上述各挥发油原料;
②将上述每 1种挥发油原料内单独的加入冰片, 即得所述的单味挥发油 类组合物, 若需混合的挥发油类组合物时, 将单味的挥发油类组合物相互混合 后即得。
10、 根据权利要求 1所述的药疗鞋, 其特征在于: 所述的液体药剂、 挥发油类组合物 2 种剂型可以混合后滴入所述的空的容器中使用; 也可以将 所述的液体药剂、挥发油类组合物 2种剂型混合后滴入所述的装有粉剂药粉的 容器中使用; 还可以将所述的液体药剂、 挥发油类组合物 2种剂型各自单独的 滴入所述的装有粉剂药粉的容器中使用。
PCT/CN2008/001542 2008-07-23 2008-08-28 药疗鞋 WO2010009582A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08800540.0A EP2311340B1 (en) 2008-07-23 2008-08-28 Medical footwear

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810134230.1 2008-07-23
CN2008101342301A CN101632509B (zh) 2008-07-23 2008-07-23 药疗鞋

Publications (1)

Publication Number Publication Date
WO2010009582A1 true WO2010009582A1 (zh) 2010-01-28

Family

ID=41569985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/001542 WO2010009582A1 (zh) 2008-07-23 2008-08-28 药疗鞋

Country Status (3)

Country Link
EP (1) EP2311340B1 (zh)
CN (1) CN101632509B (zh)
WO (1) WO2010009582A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2483458A (en) * 2010-09-08 2012-03-14 Alton Brown Deodorizing cartridge suitable for heels

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105455296B (zh) * 2015-08-19 2017-10-17 乌力吉 具有药疗功能的自我痊愈调理鞋
CN105768358B (zh) * 2015-11-20 2017-10-27 乌力吉 具有药磁疗功能的自我痊愈调理鞋
CN109674142A (zh) * 2019-02-14 2019-04-26 上海交通大学 一种能持续给药或施加电刺激的3d打印糖尿病足鞋垫
CN111802749A (zh) * 2019-04-11 2020-10-23 河南雅竹装饰工程有限公司 一种治疗脚气脚臭的中药按摩鞋垫
CN110604369A (zh) * 2019-07-23 2019-12-24 范伟 一种汉麻中草药足护按摩养生抑菌鞋垫及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2096239U (zh) * 1991-04-27 1992-02-19 福建省晋江县鸿达鞋业有限公司 祛臭香味磁疗鞋底
WO1994023766A1 (en) * 1993-04-13 1994-10-27 Schering-Plough Healthcare Products, Inc. Foot and shoe deodorizer
CN1127617A (zh) * 1995-10-30 1996-07-31 乌力吉 永磁医疗保健鞋
CN1142341A (zh) * 1996-07-03 1997-02-12 乌力吉 药磁医疗保健鞋
CN2631500Y (zh) * 2003-06-27 2004-08-11 河北科技大学 一种缓释型二氧化氯空气消毒盒
WO2007010583A1 (en) * 2005-07-21 2007-01-25 Generazione S.R.L. Footwear structure with improved comfortableness
CN201076056Y (zh) * 2007-09-27 2008-06-25 郭文和 足底按摩拖鞋

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3417494A (en) * 1967-08-01 1968-12-24 Claff Clarence Lloyd Insole
CN2161104Y (zh) * 1993-06-26 1994-04-13 霍静利 药物保健按摩鞋
CN2195873Y (zh) * 1994-04-27 1995-05-03 霍静利 多用药物保健按摩鞋垫
DE29605413U1 (de) * 1996-03-23 1996-05-30 Hetze Peter Anordnung zum Verhindern unangenehmer Gerüche in Schuhen
CN2270380Y (zh) * 1996-07-10 1997-12-17 徐力生 保健皮鞋鞋底
CN2277671Y (zh) * 1997-01-15 1998-04-08 李国良 保健鞋垫
CN2300409Y (zh) * 1997-06-25 1998-12-16 乌力吉 按摩理疗鞋
GB2350279A (en) * 1999-05-24 2000-11-29 Internet World Sport Footwear with solid or gel medicament
ITMC20040120A1 (it) * 2004-09-27 2004-12-27 Riccardo Diomedi Plantare multifunzionale totalmente scomponibile,
KR100826618B1 (ko) * 2006-07-25 2008-05-02 강석철 신발용 약제 팩 및 이를 구비한 신발

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2096239U (zh) * 1991-04-27 1992-02-19 福建省晋江县鸿达鞋业有限公司 祛臭香味磁疗鞋底
WO1994023766A1 (en) * 1993-04-13 1994-10-27 Schering-Plough Healthcare Products, Inc. Foot and shoe deodorizer
US5732485A (en) * 1993-04-13 1998-03-31 Schering-Plough Healthcare Products, Inc. Foot and shoe deodorizer
CN1127617A (zh) * 1995-10-30 1996-07-31 乌力吉 永磁医疗保健鞋
CN1142341A (zh) * 1996-07-03 1997-02-12 乌力吉 药磁医疗保健鞋
CN2631500Y (zh) * 2003-06-27 2004-08-11 河北科技大学 一种缓释型二氧化氯空气消毒盒
WO2007010583A1 (en) * 2005-07-21 2007-01-25 Generazione S.R.L. Footwear structure with improved comfortableness
CN201076056Y (zh) * 2007-09-27 2008-06-25 郭文和 足底按摩拖鞋

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2483458A (en) * 2010-09-08 2012-03-14 Alton Brown Deodorizing cartridge suitable for heels

Also Published As

Publication number Publication date
EP2311340A1 (en) 2011-04-20
CN101632509B (zh) 2012-01-11
EP2311340A4 (en) 2014-05-21
CN101632509A (zh) 2010-01-27
EP2311340B1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
WO2010009582A1 (zh) 药疗鞋
CN101632750B (zh) 一种填精补髓、益肾扶阳的中药组合物及其制备方法
CN101352505B (zh) 一种治疗跌打伤科接骨散
CN201238665Y (zh) 药疗鞋
CN101361819A (zh) 一种新型舒筋止痛的外用中药搽剂
CN104173591B (zh) 普洱茶精油水凝胶贴及其制作方法
CN104606347A (zh) 一种治疗肝肾阴虚型绝经后骨质疏松症的中药制剂
CN115364151B (zh) 一种治疗中风后偏瘫的中药组合物及其应用
CN101628096B (zh) 一种治疗小儿腹泻的中药组合物
CN1814201A (zh) 一种治疗颈椎病的中药巴布剂及其制备方法
CN108815363A (zh) 一种安神助眠的中药贴剂
CN105327092B (zh) 一种治疗颈源性失眠的中药组合物及其应用
CN100382810C (zh) 一种用于治疗冠心病类的滴丸剂及其制备方法
CN103285162A (zh) 用于补肾壮阳的中药组合物及其制备方法
CN112076297A (zh) 一种安胎止吐的药物组合物及其制备方法和用途
CN102512586B (zh) 一种滋补阴阳气血的中药制剂
CN103251891A (zh) 一种治疗气滞血瘀型不稳定性心绞痛的中药外用膏剂
CN100998744A (zh) 一种治疗小儿多动症的中成药
CN1515303A (zh) 治疗冠心病、心绞痛的中药制剂及其制作方法
CN115737730B (zh) 一种用于治疗足底筋膜炎的中药组合物及其制备方法
CN217012959U (zh) 一种药物按摩保健鞋垫
CN101422489A (zh) 一种治疗腺癌的中药制剂
CN115844972B (zh) 一种用于治疗骨质疏松症的脐贴及其制备方法
CN102204966B (zh) 一种舒筋止痛的外用中药搽剂
CN100571722C (zh) 治疗肾虚及更年期综合症的药物组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08800540

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008800540

Country of ref document: EP